Celularity Inc. (CELU)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Celularity Inc. (CELU) trades at $0.79 with AI Score 22/100 (Grade F). Celularity Inc. is a clinical-stage biotechnology company focused on developing placental-derived cell therapies for various diseases. Market cap: $19.00M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CELU: CELU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CELU against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CELU: the 7 perspectives are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Celularity Inc. (CELU) Healthcare & Pipeline Overview
Celularity Inc. is pioneering off-the-shelf placental-derived cell therapies, targeting cancer and other diseases, with a diverse clinical pipeline and a commitment to innovative regenerative medicine solutions.
What Is the Investment Thesis for CELU?
Celularity Inc. is positioned for growth through its innovative approach to cell therapy, targeting significant market opportunities in oncology and regenerative medicine. The company’s lead programs, including CYCART-19 and CYNK-001, are in various stages of clinical trials, with potential market sizes in the billions for oncology therapies alone. The global CAR-T cell therapy market is projected to reach $9.5 billion by 2027, while the NK cell therapy market is also expected to grow substantially. Celularity's unique placental-derived therapies offer competitive advantages in terms of accessibility and scalability, potentially leading to faster commercialization timelines. However, risks include regulatory challenges and the competitive landscape, which could impact the pace of clinical development and market entry. The company's ability to navigate these challenges while advancing its clinical pipeline will be critical in driving shareholder value.
Based on FMP financials and quantitative analysis
CELU Key Highlights
- Market cap of $19.00M reflects the early-stage nature of the company.
- Profit margin of -345.4% indicates substantial investment in R&D as it develops its clinical pipeline.
- Gross margin of 76.0% suggests high potential profitability once products are commercialized.
- Beta of 0.45 indicates lower volatility compared to the broader market, appealing to risk-averse investors.
- No dividend yield as the company reinvests earnings into growth initiatives.
Who Are CELU's Competitors?
CELU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $61.78 | +2.83% | $5.96B | 44 |
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| EDIT Editas Medicine, Inc. | $3.66 | +0.27% | $358.30M | — |
| ALNY Alnylam Pharmaceuticals, Inc. | $313.04 | +0.08% | $41.79B | 95 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CELU's Key Strengths?
- Innovative approach leveraging placental-derived cells for therapy.
- Strong clinical pipeline with multiple promising candidates.
- High gross margin potential once therapies are commercialized.
- Established brand in bio-banking and cell storage services.
What Are CELU's Weaknesses?
- Negative profit margins due to heavy R&D investments.
- Limited market presence compared to larger competitors.
- Dependence on successful clinical trial outcomes for growth.
- Relatively small employee base may limit operational scalability.
What Could Drive CELU Stock Higher?
- Results from Phase I clinical trials for CYCART-19 expected in late 2026.
- Initiation of Phase I/IIa trials for CYNK-001 in glioblastoma multiforme anticipated by Q4 2026.
- Development of APPL-001 and PDA-002 in pre-clinical stages, with potential for future clinical trials.
- Expansion of LifebankUSA services to enhance bio-banking revenue streams.
- Continued partnerships with healthcare providers to broaden market reach.
What Are the Key Risks for CELU?
- Financial-distress signal — its Altman Z-Score of -16.00 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges could delay the approval of key therapies.
- Competition from established biotech firms may impact market share.
- Clinical trial failures could adversely affect the company's future prospects.
- Changes in healthcare policies may influence reimbursement for cell therapies.
What Are the Growth Opportunities for CELU?
- Expansion of CYCART-19: Celularity's lead CAR-T therapy is currently in Phase I trials, targeting B-cell malignancies. The global CAR-T market is projected to grow to $9.5 billion by 2027, providing a substantial revenue opportunity if the therapy successfully advances through clinical trials and gains regulatory approval.
- Development of CYNK-001: This placental-derived NK cell therapy is in Phase I trials for acute myeloid leukemia and glioblastoma. The NK cell therapy market is expected to grow significantly, with increasing recognition of its potential in oncology, presenting a lucrative opportunity for Celularity.
- Market for surgical and wound care products: Celularity's existing products like Biovance and Interfyl cater to the surgical and wound care markets, which are projected to grow due to an aging population and increased surgical procedures. This segment could provide steady revenue streams while the company develops its more experimental therapies.
- BioBanking services growth: With the increasing demand for stem cell storage services, Celularity's LifebankUSA brand is positioned to capture a growing market. The global stem cell banking market is expected to expand, driven by rising awareness and advancements in regenerative medicine.
- Pre-clinical advancements: The development of APPL-001 and PDA-002 for Crohn's disease and muscular dystrophy, respectively, could open new therapeutic avenues. As these conditions have limited treatment options, successful development could lead to significant market opportunities.
What Opportunities Does CELU Have?
- Expanding market for CAR-T and NK cell therapies.
- Growing demand for regenerative medicine solutions.
- Potential partnerships with larger pharmaceutical companies.
- Increasing awareness and adoption of stem cell therapies.
What Threats Does CELU Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles in obtaining approvals for new therapies.
- Market volatility affecting funding for clinical trials.
- Rapid technological advancements may outpace current offerings.
What Are CELU's Competitive Advantages?
- Unique focus on placental-derived cell therapies, differentiating it from competitors.
- Strong intellectual property portfolio protecting its innovative therapies.
- Established brand recognition in the bio-banking sector through LifebankUSA.
- Robust clinical pipeline with multiple therapies in various stages of development.
- Experienced leadership team with a track record in biotechnology and regenerative medicine.
What Does CELU Do?
Founded in 2016 and headquartered in Florham Park, New Jersey, Celularity Inc. is a clinical-stage biotechnology company dedicated to developing off-the-shelf placental-derived allogeneic cell therapies. The company operates through three primary segments: Cell Therapy, Degenerative Disease, and BioBanking. Its innovative approach leverages the unique properties of placental cells, which are rich in stem cells, to create therapies that can potentially transform the treatment landscape for cancer, immune disorders, and infectious diseases. Celularity's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy currently in Phase I clinical trials for B-cell malignancies. Additionally, CYNK-001, an unmodified natural killer (NK) cell therapy, is being evaluated in Phase I trials for acute myeloid leukemia and in Phase I/IIa trials for glioblastoma multiforme and COVID-19. The company also has CYNK-101, a genetically modified NK cell therapy in Phase I clinical trials for HER2+ gastric and gastroesophageal cancers, as well as APPL-001 and PDA-002, both in pre-clinical stages for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. Beyond its therapeutic developments, Celularity offers products for surgical and wound care markets, such as Biovance and Interfyl, and provides stem cell storage services under the LifebankUSA brand. With a focus on innovation and a commitment to addressing unmet medical needs, Celularity is positioned to make significant contributions to the field of regenerative medicine.
What Products and Services Does CELU Offer?
- Develops placental-derived allogeneic cell therapies for cancer and other diseases.
- Operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
- Conducts clinical trials for innovative therapies targeting various malignancies and diseases.
- Sells and licenses products for surgical and wound care markets.
- Provides stem cell collection and storage services under LifebankUSA.
- Focuses on regenerative medicine with a commitment to addressing unmet medical needs.
How Does CELU Make Money?
- Generates revenue through the sale of surgical and wound care products.
- Offers stem cell storage services, creating a recurring revenue stream.
- Licenses its innovative therapies to other healthcare providers and institutions.
- Engages in clinical trials to develop and commercialize new therapies, aiming for regulatory approvals.
- Explores partnerships and collaborations to expand its market reach and enhance product offerings.
What Industry Does CELU Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in genetic therapies and a rising demand for innovative treatment solutions. The global biotechnology market is expected to reach $2.4 trillion by 2028, with significant investments flowing into cell and gene therapies. Celularity Inc. operates within this dynamic landscape, focusing on placental-derived therapies, a niche that sets it apart from traditional cell therapy companies. As the demand for effective cancer treatments continues to rise, Celularity's innovative approach positions it favorably against competitors who are also vying for market share in the oncology and regenerative medicine sectors.
Who Are CELU's Key Customers?
- Healthcare providers seeking innovative therapies for cancer treatment.
- Patients requiring advanced wound care solutions.
- Research institutions focused on regenerative medicine.
- Hospitals and clinics utilizing stem cell storage services.
- Biotechnology firms interested in licensing innovative cell therapies.
Celularity Inc. Financial Trajectory
Celularity Inc. (CELU) reported $4.1M in revenue for Q4 2025, a decline of 22.3% compared to the prior quarter. The company recorded a net loss of $24.4M, with diluted EPS of $-0.95. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CELU averaged $-0.92 in diluted EPS.
Company Profile
Celularity Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Florham Park, US. The company is led by CEO Robert Joseph Hariri. CELU has traded publicly since 2019.
How Celularity Inc. Is Valued
Celularity Inc. carries a market capitalization of $19.00M, placing it in the micro-cap category. Relative to its peer group, CELU's quantitative score of 22/100 is below the peer average of 69/100.
ROE 411%Key Financial Metrics
Return on equity for Celularity Inc. stands at 411.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -85.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -92.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Celularity Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.00 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Celularity Inc. revenue of about $44.0M for fiscal 2026, with EPS near $-2.75.
CELU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a belief in its growth potential.
- Community sentiment has shifted positively, with discussions around innovative therapies gaining traction and excitement.
- There is increasing interest in Celularity's unique approach to cell-based therapies, which could position it favorably in a growing market.
- Recent partnerships and collaborations have been highlighted, showcasing the company's commitment to advancing its research and development efforts.
Bear Case
- Concerns persist about the company's ability to achieve profitability in a competitive landscape, leading to skepticism among some investors.
- Negative sentiment has emerged regarding the pace of product development, with some community members questioning timelines and milestones.
- Market perception remains cautious, influenced by broader economic uncertainties affecting biotech investments.
- Recent regulatory challenges have raised eyebrows, creating an atmosphere of uncertainty around the approval of key therapies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $4M | -$24M | -$0.95 |
| Q3 2025 | $5M | -$23M | -$0.88 |
| Q2 2025 | $6M | -$25M | -$1.02 |
| Q1 2025 | $11M | -$20M | -$0.84 |
Based on FMP financials and quantitative analysis
CELU Latest News
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · May 1, 2026
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 10, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 11, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Jun 22, 2022
CELU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CELU.
Price Targets
Wall Street price target analysis for CELU.
CELU MoonshotScore
What does this score mean?
The MoonshotScore rates CELU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Celularity Inc. Analysis
Leadership: Robert Joseph Hariri
CEO
Robert Joseph Hariri is a seasoned entrepreneur and physician with extensive experience in biotechnology and regenerative medicine. He co-founded Celularity Inc. and has played a pivotal role in its strategic direction and growth. Hariri holds an M.D. from the University of Medicine and Dentistry of New Jersey and a Ph.D. in Molecular Genetics from the University of Pennsylvania. His career includes leadership roles in various biotech firms, where he has focused on developing innovative therapies and advancing clinical research.
Track Record: Under Hariri's leadership, Celularity has developed a robust clinical pipeline and established itself as a leader in placental-derived therapies. His strategic vision has driven the company’s focus on innovative solutions for unmet medical needs, leading to several key partnerships and advancements in clinical trials.
Celularity Inc. Healthcare Stock: Key Questions Answered
What does Celularity Inc. do?
Celularity Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking, with a diverse pipeline of therapies in various stages of clinical development.
What is Celularity Inc.'s drug pipeline status?
Celularity Inc. has a robust clinical pipeline with several therapies in development. Its lead programs include CYCART-19, currently in Phase I trials for B-cell malignancies, and CYNK-001, which is being evaluated for acute myeloid leukemia and glioblastoma. The company also has pre-clinical candidates such as APPL-001 and PDA-002 targeting Crohn's disease and muscular dystrophy, respectively.
What are the main risks for CELU?
Celularity Inc. faces several risks, including regulatory challenges that could hinder the approval process for its therapies, intense competition from established biotechnology firms, and the potential for clinical trial failures that could impact future growth. Additionally, changes in healthcare policies may affect reimbursement rates for innovative cell therapies, posing further challenges for the company's market penetration.
What are the key factors to evaluate for CELU?
Celularity Inc. (CELU) holds an AI score of 22/100 (low). Not financial advice.
How frequently does CELU data refresh on this page?
CELU prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CELU's recent stock price performance?
Celularity Inc. (CELU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative approach leveraging placental-derived cells for therapy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CELU overvalued or undervalued right now?
Valuing Celularity Inc. (CELU) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CELU?
Before investing in Celularity Inc. (CELU), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on the latest available data and may be subject to change.